The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial
Abstract
Abstract Rationale In septic animal models mesenchymal stem (stromal) cells (MSCs) modulate inflammation, enhance tissue repair and pathogen clearance, and reduce death. Objectives To conduct a phase I dose escalation trial of MSCs in septic shock with the primary objective of examining the safety and tolerability of MSCs. Methods We enrolled nine participants within 24 hours of admission to the ICU. A control cohort of 21 participants was enrolled before starting the MSC interventional cohort to characterize expected adverse events (AEs) and to serve as a comparator for the intervention cohort. Three separate MSC dose cohorts, with three participants per cohort, received a single intravenous dose of 0.3, 1.0, and 3.0 × 106 cells/kg. A prespecified safety plan monitored participants for the occurrence of AEs; cytokines were collected at prespecified time points. Measurements and Main Results Ages of participants in the interventional versus observational cohorts were median of 71 (range, 38–91) and 61 (range, 23–95). Acute Physiology and Chronic Health Evaluation scores were median of 25 (range, 11–28) and 26 (range, 17–32). MSC doses ranged from 19 to 250 million cells. There were no prespecified MSC infusion–associated or serious unexpected AEs, nor any safety or efficacy signals for the expected AEs or the measured cytokines between the interventional and observational cohorts. Conclusions The infusion of freshly cultured allogenic bone marrow–derived MSCs, up to a dose of 3 million cells/kg (250 million cells), into participants with septic shock seems safe. Clinical trial registered with www.clinicaltrials.gov (NCT02421484).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Németh, K., Leelahavanichkul, A., Yuen, P. S. T., Mayer, B., Parmelee, A., Doi, K., Robey, P. G., Leelahavanichkul, K., Koller, B. H., Brown, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1905 · Cited by 2,364 · cited 1×
“7) Infectious source, n (%) Lung 8 (38) 3 (33) Intraabdominal 6 (29) 3 (33) Urinary 2 (10) 1 (11) Skin 1 (5) 0 (0) Other 4 (19) 2 (22) Time to enrollment from ICU admission, h, median (range) 19 (5 to 28) 24 (11 to 28)”
Dose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Why have clinical trials in sepsis failed?
Marshall, J. C. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.01.007 · Cited by 805
Self-citationHospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007
Lagu, T., Rothberg, M. B., Shieh, M.-S., Pekow, P. S., Steingrub, J. S., & Lindenauer, P. K. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e318232db65 · Cited by 679
François, M., Copland, I. B., Yuan, S., Romieu-Mourez, R., Waller, E. K., & Galipeau, J. (2012) · Cytotherapy · doi:10.3109/14653249.2011.623691 · Cited by 375 · cited 6×
“8) 244 (132-291) 240 (72-316) 130 (45-157) 21 (6-83) 2.”
BackgroundInfluential
Cited by
Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
Shu, L., Niu, C., Li, R., Huang, T., Wang, Y., Huang, M., Ji, N., Zheng, Y., Chen, X., Shi, L., et al. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01875-5 · Cited by 303
Dabrowska, S., Andrzejewska, A., Janowski, M., & Lukomska, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591065 · Cited by 282
Metadata
- Authors
- McIntyre, L. A., Stewart, D. J., Mei, S. H. J., Courtman, D., Watpool, I., Granton, J., Marshall, J., dos Santos, C., Walley, K. R., Winston, B. W., Schlosser, K., & Fergusson, D. A.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-01
- Volume
- 197
- Issue
- 3
- Pages
- 337-347
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2758526267
- Cited by
- 161
- References
- 5
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. https://app.cochat.ai/papers/10.1164/rccm.201705-1006oc
- The paper
- McIntyre, L. A., Stewart, D. J., Mei, S. H. J., Courtman, D., Watpool, I., Granton, J., Marshall, J., dos Santos, C., Walley, K. R., Winston, B. W., Schlosser, K., & Fergusson, D. A. (2018). Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201705-1006oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.